Gap 26

Pricing Availability   Qty
Cat.No. 1950 - Gap 26 | Val-Cys-Tyr-Asp-Lys-Ser-Phe-Pro-Ile-Ser-His-Val-Arg | CAS No. 197250-15-0
Description: Gap junction blocker; inhibits smooth muscle contraction and IP3-mediated ATP release
Datasheet
Citations (3)
Reviews
Literature

Biological Activity

Peptide, corresponding to residues 63 - 75 of connexin 43, which is a gap junction blocker. Attenuates rhythmic contractile activity of rabbit arterial smooth muscle (IC50 = 28.4 μM). Also inhibits IP3-induced ATP release, without inhibiting gap junctional coupling in endothelial cells.

Technical Data

M. Wt 1550.79
Formula C70H107N19O19S
Sequence VCYDKSFPISHVR
Storage Desiccate at -20°C
CAS Number 197250-15-0
PubChem ID 25088334
InChI Key FDPIMWZHGJNESB-VCSXYVMHSA-N
Smiles [H]N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solubility Soluble to 2 mg/ml in water

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:

References

References are publications that support the biological activity of the product.

Braet et al (2003) Photoliberating inositol-1,4,5-trisphosphate triggers ATP release that is blocked by the connexin mimetic peptide gap 26. Cell Calcium 33 37 PMID: 12526886

Chaytor et al (1997) Peptides homologous to extracellular loop motifs of connexin 43 reversibly abolish rhythmic contractile activity in rabbit arteries. J.Physiol. 503 99 PMID: 9288678


If you know of a relevant reference for Gap 26, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Gap Channel Blockers

Keywords: Gap 26, Gap 26 supplier, Gap, junction, blockers, connexin, 43, channels, modulators, Gap26, Channels, 1950, Tocris Bioscience

3 Citations for Gap 26

Citations are publications that use Tocris products. Selected citations for Gap 26 include:

Jones et al (2015) Evidence for bystander signalling between human trophoblast cells and human embryonic stem cells. Sci Rep 5 11694 PMID: 26170169

Sakatani et al (2008) Neural-activity-dependent release of S100B from astrocytes enhances kainate-induced gamma oscillations in vivo. J Neurosci 28 10928 PMID: 18945900

Thuringer et al (2015) Oncogenic extracellular HSP70 disrupts the gap-junctional coupling between capillary cells. BMC Vet Res 6 10267 PMID: 25868858


Do you know of a great paper that uses Gap 26 from Tocris? Please let us know.

Reviews for Gap 26

There are currently no reviews for this product. Be the first to review Gap 26 and earn rewards!

Have you used Gap 26?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Epilepsy

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.